RecruitingNot applicableNCT06267391

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

Studying MODY

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Endogenex, Inc.
Principal Investigator: Lian Cunningham, MD, PhD
lcunningham@endogenex.com
Intervention: ReCET Treatment(device)
Enrollment: 264 target
Eligibility: 22-70 years · All sexes
Timeline: 2024 – 2026

Study locations (30)

University of Alabama, Birmingham, Alabama, United States
Central Alabama Research, Birmingham, Alabama, United States
Velocity Clinical Research, Gardena, Gardena, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
UCLA, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian - Digestive Health Institute, Newport Beach, California, United States
Velocity Clinical Research, Panorama City, Panorama City, California, United States
Velocity Clinical Research, Hallandale Beach, Hallandale, Florida, United States
Mayo Clinic, Jacksonville, Florida, United States
Universal Axon Clinical Research LLC, Miami, Florida, United States
University of Miami, Miami, Florida, United States
Quantum Clinical Research, Miami Beach, Florida, United States
West Orange Endocrinology, Ocoee, Florida, United States
Advent Health, Orlando, Florida, United States
Orlando Health, Orlando, Florida, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06267391 on ClinicalTrials.gov

Other trials for MODY

Additional recruiting or active studies for the same condition.

See all trials for MODY →

← Back to all trials